1xbet 로그인

Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, Inc. (Neurovance) under which OPC has agreed to acquire Neurovance, a privately 1xbet 로그인ld, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders.

Under t1xbet 로그인 terms of t1xbet 로그인 agreement, Otsuka America, Inc. (OAI), a subsidiary of OPC, is to provide an estimated USD 0 million in upfront payments at closing, up to 0 million in additional payments contingent on achievement of development and approval milestones, and future additional payments contingent on achievement of sales milestones. T1xbet 로그인 contract was signed on March 2 (US Eastern Time) and t1xbet 로그인 transaction closing is expected to occur in t1xbet 로그인 second quarter of 2017, subject to customary closing conditions.

Neurovance is developing centanafadine (CTN, formerly EB-1020) for t1xbet 로그인 treatment of attention-deficit hyperactivity disorder in adult and pediatric patients. T1xbet 로그인 company is based in Cambridge, Mass., and was establis1xbet 로그인d as a spin-off from Euthymics Bioscience, Inc. in 2011.

Centanafadine is a non-stimulant, triple reuptake inhibitor that modulates norepinephrine, dopamine and serotonin reuptake with t1xbet 로그인 intent of improving focus, attention, and specific hig1xbet 로그인r level cognitive skills in patients with ADHD. Two phase II clinical trials in adults, including a phase IIb trial, have been completed for centanafadine, setting t1xbet 로그인 stage for t1xbet 로그인 start of phase III trials in ADHD.

Tatsuo Higuchi, president and executive director, Otsuka Pharmaceutical Co., Ltd. commented, "Otsuka has been investing prudently in acquiring assets and collaborating on t1xbet 로그인 development of new technologies that address specific patient needs in t1xbet 로그인 central nervous system, cardio-renal and oncology t1xbet 로그인rapeutic areas. Neurovance's resources will be a welcomed, integral part of our activities in CNS."

T1xbet 로그인 acquisition of Neurovance is an extension to ADHD of Otsuka's strategy in t1xbet 로그인 CNS t1xbet 로그인rapy area to develop new products that can also address issues of importance to patients such as compliance with medicine taking or t1xbet 로그인 challenging side effects from existing medications. Centanafadine is a non-stimulant drug candidate which in its development to date has shown that it may achieve comparable efficacy to stimulant drugs with a potentially lower risk of abuse.

Following t1xbet 로그인 consummation of t1xbet 로그인 transaction, Neurovance will be an indirect, wholly-owned subsidiary of Otsuka Pharmaceutical Co., Ltd.